TITLE

Review: Cholesterol-lowering treatment with statins reduces all-cause mortality in persons at risk

PUB. DATE
May 2006
SOURCE
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p62
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study which found that cholesterol-lowering treatment with statins reduces all-cause and coronary heart disease mortality in persons at risk. Unconfounded randomized controlled trials (RCTs) that compared a statin with a control condition were chosen for the study. 14 RCTs met the selection criteria. Meta-analyses assessed the effects on clinical outcome in each trial weighted by the absolute low-density lipoprotein cholesterol difference in that trial at the end of the first year of follow-up.
ACCESSION #
21490775

 

Related Articles

  • Emerging Therapies and Their Role in Comprehensive Lipid Management. Vinall, Maria // MD Conference Express;Oct2011, p6 

    The article focuses on the clinical trials which aimed to evaluate low-density lipoprotein cholesterol (LDL-C) targets and assess their significance on treatment approaches. It mentions the result of the PROVE-IT trial which support intensive statin therapy after acute coronary syndrome (ACS),...

  • The importance of intensive lowering of LDL cholesterol -- the role of potent statins. Reiner, �eljko // Cardiologia Croatica;2012, Vol. 7 Issue 5/6, p187 

    Increased LDL cholesterol is the main risk factor for cardiovascular (CVD) diseases, particularly coronary heart disease (CHD) and myocardial infarction (MI). The treatment of choice for elevated LDL cholesterol are statins. Large clinical trials have shown that lowering of LDL cholesterol is...

  • Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart Disease. Hu, M.; Mak, V. W. L.; Chu, T. T. W.; Waye, M. M. Y.; Tomlinson, B. // Current Pharmacogenomics & Personalized Medicine;2009, Vol. 7 Issue 1, p1 

    The statins are the most important group of drugs for lipid-lowering therapy in the prevention of coronary heart disease. Greater reductions in LDL-cholesterol appear to be associated with greater benefits but the clinical efficacy and safety of statin treatment varies considerably from person...

  • Rosuvastatin Plus Ezetimibe. Crawford, Michael H. // Clinical Cardiology Alert;Jun2007, Vol. 26 Issue 6, p44 

    WHEN BASELINE LDL CHOLESTEROL LEVELS ARE high, achievement of target levels, especially < 70 mg/dl can be difficult. Thus, the EXamination of Potential Lipid-modifying effects Of Rosuvastatin in combination with Ezetimibe versus Rosuvastatin alone (EXPLORER) study was conducted at 58 centers in...

  • A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport. Temel, Ryan E.; Mark Brown, J. // Annals of Gastroenterology & Hepatology;2011, Vol. 9 Issue 96, p5946 

    Reduction of low-density lipoprotein-cholesterol through statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Major efforts are now focused on therapies...

  • A new framework for reverse cholesterol transport: Non-biliary contributions to reverse cholesterol transport. Temel, Ryan E.; Mark Brown, J. // Annals of Gastroenterology & Hepatology;2011, Vol. 9 Issue 93, p5946 

    Reduction of low-density lipoprotein-cholesterol through statin therapy has only modestly decreased coronary heart disease (CHD)-associated mortality in developed countries, which has prompted the search for alternative therapeutic strategies for CHD. Major efforts are now focused on therapies...

  • The contrOL of dYslipideMia in outPatlent clinics in GreeCe (OLYMPIC) Study. Diamantopoulos, E. J.; Athyros, V. G.; Yfanti, G. K.; Migdalis, E. N.; Elisaf, M.; Vardas, P. E.; Manolis, A. S.; Karamitsos, D. T.; Ganotakis, E. S.; Hatseras, D. // Angiology;Nov/Dec2005, Vol. 56 Issue 6, p731 

    The objective of this study was to determine the proportion of Greek patients referred to outpatient clinics for dyslipidemia who achieved the low-density lipoprotein cholesterol (LDL-C) goal defined by the National Cholesterol Education Program Adult Treatment Panel Ill (NCEP-ATP Ill)...

  • Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population. SONG, JESSICA C.; WANG, CLIFFORD C.; YI-CHAO HUANG; SANCHEZ, JEANNETTE; NGUYEN, THERESA; KHAN, SHAMIMA; MYO-KYOUNG KIM; LI, PHOEBE // American Journal of Health-System Pharmacy;4/1/2007, Vol. 64 Issue 7, p767 

    The article studies the use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population. It shows that despite the use of maximum-dose simvastatin or atorvastatin, target low-density-lipoprotein cholesterol goals were not achieved and statin use was not adequately monitored...

  • Clinical Positioning of HMG-CoA Reductase Inhibitors in Lipid Management Protocols. Cziraky, M. // PharmacoEconomics;1998 Supplement 3, Vol. 14 Issue 4, p29 

    Drug treatment of dyslipidaemia has progressed dramatically over the past decade. Of the available drugs, HMG-CoA reductase inhibitors (statins) have emerged as very effective and important treatments for dyslipidaemia. These agents potently reduce low density lipoprotein (LDL) cholesterol...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics